2022 Award


The International Prize for Scientific Research Arrigo Recordati 2022

Over the last fifteen years, Recordati has made the Rare Diseases field a health priority and has increased its commitment worldwide through its dedicated subsidiary Recordati Rare Diseases. The primary focus of Recordati Rare Diseases is to research, develop and market drugs for the treatment of metabolic genetic disorders. Recently, this portfolio has been enhanced with additional innovative products in the area of rare endocrine diseases.

To reflect its strong commitment in the field of endocrinology, Recordati decided that the 2022 edition of Arrigo Recordati International Prize for Scientific Research will be dedicated to the promotion and recognition of excellence in research on pituitary disorders.

Young investigators of all nationalities working in the area of pituitary disorders are eligible. They are typically junior faculty who are not more than ten years from completing their postdoctoral fellowship or clinical specialty fellowship and who are not in any way directly affiliated with a pharmaceutical company.

Basic, translational, and clinical research projects focusing pituitary disorders are eligible.

The winning project will receive a € 100,000 research grant.

Recordati recognizes the value of basic research to elucidate normal pituitary pathophysiology and the etiology of pituitary disorders, translational research to develop new diagnostics for early intervention, and clinical research to develop novel therapeutic strategies. Such research projects are sought for this competition.

Proposals should be based on strong preliminary results which support the project rationale. If a proposed experimental treatment is based on a pre-existing treatment, the project is eligible only if the treatment is being repurposed for another indication or if its formulation, or administration is changed in a major way, in order to improve treatment quality, compliance, efficacy, safety or any other significant patient benefit.


2022 REVIEW COMMITTEE

Applications will be reviewed by an independent panel of internationally recognized experts who have provided leadership throughout their long careers in the field of Rare Diseases

For the 2022 Award, the Review Committee is composed of:
 

 


Chairman: Robert J. Desnick Ph.D, M.D., Dean for Genetic and Genomic Medicine, Professor and Chair Emeritus Department of Genetics & Genomic Sciences, Mount Sinai School of Medicine, New York, N.Y., USA


Robert J. Desnick Ph.D, M.D.

Robert J. Desnick Ph.D, M.D.

Icahn School of Medicine at Mount Sinai
Mount Sinai Health System, New York, NY

Robert J. Desnick is Dean for Genetic and Genomic Medicine and Professor and Chairman Emeritus of the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai.

In 1977, he joined the Mount Sinai faculty as the Arthur J. and Nellie Z. Cohen Professor of Pediatrics and Genetics, and Chief of Medical and Molecular Genetics. From 1993- 2011, he was the first Chairman of the Department of Genetics and Genomic Sciences at Mount Sinai. In 2011 he became the Dean for Genetics and Genomic Medicine.

Dr. Desnick’s research interests include lysosomal storage diseases (LSDs) and the inborn errors of heme biosynthesis, the porphyrias, and in particular, their treatment. His research efforts led to the Federal Drugs Administration (FDA) - and European Medicine Agency (EMA) - approval of enzyme replacement therapy (ERT) for Fabry disease (Fabrazyme) and on-going ERT clinical trials (FDA “Breakthrough” status) for Niemann- Pick B disease, both in partnership with Genzyme. In addition, he was a scientific founder of Amicus Therapeutics (NASDAQ; FOLD), which is developing oral pharmacologic chaperone therapy for Fabry disease (EMA-approved in 2016), Pompe disease, and other disorders. Currently, his laboratory is using gene editing technology to engineer gene therapy in the mouse model of Fabry disease with Sangamo Therapeutics.

For the porphyrias, he co-developed with Alnylam Pharmaceuticals an RNAi therapy for the acute hepatic porphyrias, performed the preclinical studies, and co-designed the ongoing clinical trials. He also served as Principal Investigator for Clinuvel Pharmaceuticals’ Phase 2 and 3 multisite clinical trials of afamelanotide, a “first-in-class” synthetic peptide for the treatment of the Erythropoietic Porphyrias, which was recently EMA-approved and pending FDA approval. He also served as the Chairman of the Scientific Advisory Committee (SAC) of Synageva Biopharma and currently serves as SAC Chair for Kiniksa Pharmaceuticals. In addition, his research includes genomics, pharmacogenomics, and personalized medicine. He has published over 740 research papers and chapters, including nine edited books. He is an elected Fellow of the American Association for the Advancement of Science and an elected member of the National Academy of Medicine.

 



Andrea Giustina, M.D, Full Professor and Chair Institute of Endocrinology and Metabolic Sciences, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy


Andrea Giustina M.D.

Andrea Giustina M.D.

Full Professor and Chair Institute
of Endocrinology and Metabolic Sciences (IEMS)
San Raffaele Vita-Salute University,
IRCCS San Raffaele Hospital, Milan, Italy

Dr. Giustina received his Medical Degree with distinction from the University of Brescia (Italy) in 1986. From 1991 to 1994 he was in the United States as Associate Professor of Endocrinology at the University of Wisconsin, Milwaukee, and in 2002 Visiting Professor of Endocrinology, Cedars Sinai Medical Center, UCLA, Los Angeles. At the University of Brescia, he rose to become Full Professor of Internal Medicine in 2007. He moved to San Raffaele Vita-Salute University in Milan in January 2017 where he is Full Professor of Endocrinology and Metabolism and Pro Rector for Institutional and International Affairs.

He is Director of Postgraduate Program in Endocrinology and Metabolism at San Raffaele University and Head of the Division of Endocrinology at San Raffaele Hospital in Milan. Dr. Giustina has authored more than 400 original papers and made seminal contributions to our understanding of mechanisms regulating growth secretion, as well as disorders of both growth hormone deficiency and excess and bone neuroendocrinology. He elucidated the “Giustina effect” defined as inhibition of growth hormone secretion in the absence of circulating cortisol and its reversibility when cortisol levels are restored to normal. He also has co-authored several pituitary medicine guidelines of which those on Acromegaly criteria of cure and Cushing disease diagnosis have been cited more than 1000 times.

He was Editor-in-Chief of Endocrine, and one Editor of Pituitary, he is President of the European Society of Endocrinology and Past President of the Pituitary Society and served on the Executive Committee of the International Society of Endocrinology. He also served on the Journal managing subcommittee of the Endocrine Society and on the Editorial Board of Journal of Clinical Endocrinology and Metabolism and Clinical Endocrinology. He is a member of the Italian Superior Health Council at the Italian Ministry of Health.

 


Shlomo Melmed, M.D., ChB, Executive Vice President of Academic Affairs, Dean of the Medical Faculty and Professor of Medicine, Cedars Sinai Medical Center, Los Angeles, CA; USA
 


Shlomo Melmed, M.D., ChB

Shlomo Melmed M.D., ChB.

Dean of the Medical Faculty and Professor
of Medicine, Cedars Sinai Medical Centre,
Los Angeles, USA

Shlomo Melmed, MB, ChB, FRCP, MACP, leads Cedars-Sinai’s research and education programs, recruiting nationally recognized faculty leadership, establishing new educational programs, and maintaining the highest academic standards. Dr. Melmed holds the Helene A. and Philip E. Hixon Distinguished Chair Investigative Medicine. An international authority on pituitary medicine, he has pioneered the discovery and application of novel treatments for endocrine tumors and has authored more than 350
peer-reviewed articles.

Dr. Melmed has been a Faculty leader at Cedars-Sinai for nearly 40 years and has been the health system’s Chief Academic Officer since 1998. Dr. Melmed’s laboratory consistently has received competitive grant awards from the National Institutes of Health since 1980, and he has trained over 80 physicians, scientists and graduate students who occupy leading positions in academic endocrinology worldwide.

He is Editor-in-Chief of The Pituitary, editor of Williams Textbook of Endocrinology and is on the Editorial Board of the Journal of Clinical Investigation. He is also an Associate Dean of the UCLA School of Medicine. He is an elected member of the Association of American Physicians, the American Society of Clinical Investigation and the Endocrine Society Council. He served as President of the International Society of Endocrinology, President and founding member of the Pituitary Society, a member of the California Institute for Regenerative Medicine’s Independent Citizen’s Oversight Committee and serves on the California Life Sciences Association Board.

Dr. Melmed is a fellow of the American College of Physicians (ACP) and was elected to Master of the ACP. He also has been honoured with the Pituitary Society’s Lifetime Achievement Award. He has been named one of America’s top physicians and has received Cedars-Sinai’s Pioneer in Medicine Award. Other honours include the Transatlantic Medal from the Society of Endocrinology, the Endocrine Society Clinical Investigator Award, The Endocrine Society Outstanding Scholarly Physician Award, and the Royal Society of Medicine’s Clinical Endocrinology Trust Medal. Dr. Melmed earned a Bachelor of Medicine, Bachelor of Surgery (MB, ChB) with distinction from the University of Cape Town, South Africa. He is a diplomate of the American Board of Internal Medicine, certified in endocrinology and metabolism.

 


2022 AWARD CEREMONY

The winning project will be formally announced during an award ceremony at the European Congress of Endocrinology which will be held in Milan from 21st to 24th May 2022.
The 2022 award will be given to an outstanding, novel, basic, translational, or clinical research project focusing on pituitary disorders.
The winning project will receive a €100.000 research grant


2022 APPLICATION PROCEDURE

Application procedure will follow a two-step selection approach:
the deadline for the preselection will be on August 31st, 2021 and Full Applications must be submitted by the February 28th, 2022.

Preselection: from June 1st, 2021 to August 31st, 2021

Initial Applications in English must be submitted online in the preselection period described above and should include:
 

  • A Letter of Intent (see below) and the Project Summary Page (see below) describing the proposed project in 1200 words (plus 1 page for figures and/or tables)

The Application must be submitted at: www.prize.recordati.it

Applicants who submit an initial proposal will receive an email confirming receipt.

The Review Committee, and ad hoc experts, if needed, will evaluate all the initial proposals to determine which applicants will be invited to submit Full Research Project Application. Projects eligible for full review will be communicate to the applicant by November 20th, 2021.


2022 AWARD CRITERIA

Eligibility criteria:

  • Applicants must be within 10 years of completing their postdoctoral fellowship or clinical specialty fellowship and typically are junior faculty member of a medical school, hospital, or a research institute.

  • The applicant must be the Principal Investigator of the research project and her/ his role in the project must be clearly delineated.

  • The applicant CV should be included.

  • Applicants should use the Application Form and comply with instructions.

Exclusion criteria:

  • Studies with results only obtained in vitro cellular models.

  • Projects already awarded a Recordati Prize or supported by Recordati in the past.

  • Projects sponsored by other pharmaceutical companies.

  • Projects already completed.

Full Applications: from December 1st, 2021 to February 28th, 2022

Selected initials Applications will be invited to submit a Full Research Project Application for competitive review. The Full Application should be submitted by February 28th 2022, 23.59 CET at: www.prize.recordati.it
The Review Committee will follow and select the winning project based on the quality of the proposed research.

The Award will follow the “code of conduct” guidance to ensure reviews are conducted in a fair and equitable manner. The members of the Review Committee are bound by confidentiality rules generally applicable to such committees.

Applications from the Review Committee members or from faculty of their respective institutions will not be considered.

The Review Committee’s decision is final and there is no appeal mechanism.

2022 AWARD DETAILS

Application Form

The Application Form must include a Letter of Intent and a Project Summary Page.

The steps to apply are the following:

  1. Preselection of the initial proposals is based on the Letter of Intent and the Project Summary Page.

  2. Applicants of the selected initials proposals will be invited to submit Full Applications to compete for the Award by November 20th, 2021.

The selection of the winning project will be based on the evaluation of the Review Committee, and if necessary, ad hoc experts, who will assess the quality of the research as well as the potential impact of the results.

Letter of Intent

The Letter of Intent is an endorsement of the Principal Investigator and the proposed project by an administrative official of the Applicant’s medical school, hospital, or research institute.

Project Summary Page

In 1200 words (plus 1 page for figures and/or tables), succinctly describe the proposed project including:

  1. background, unmet need, and significance of the project;

  2. specific aims, objectives, or hypothesis;

  3. preliminary studies and data relevant to the proposed project;

  4. experimental design: description of methods and analyses to be performed for basic and translational research project. If a clinical trial is proposed, present the trial design, with primary & secondary endpoints, as well as a statistic plan. If the project involves the design of a novel device for treating a disease or monitoring therapeutic effectiveness, provide sufficient details to appreciate its design and novelty.

  5. expected results and expected timeframe for completing the project. Applicants should feel free to add any additional information/supportive data, as needed within the 1200-words limit.